AstraZeneca Holds Preliminary Talks with Bristol Myers Squibb on Potential $400 Billion Merger

oncodaily - A deal that could create the world’s fourth-largest drugmaker British pharmaceutical leader AstraZeneca has held confidential, preliminary discussions regarding a potential combination with US rival Bristol Myers Squibb(BMS). A completed […]

AI Summary: AstraZeneca entered preliminary, non-binding talks with Bristol Myers Squibb about a potential $400 billion merger, probing whether combining pipelines and scale could reshape oncology and other businesses. The discussions are early, sparking market speculation and likely regulatory scrutiny as executives weigh strategic synergies against integration complexity and antitrust risk.